CD30
Vai alla navigazione
Vai alla ricerca
CD30, conosciuto anche come TNFRSF8, è una proteina di membrana cellulare appartenente alla famiglia dei recettori per i fattori di necrosi tumorale e marker tumorali.
Questo recettore è espresso mediante attivazione, dalle cellule T e B. TRAF2 e TRAF5 possono interagire con questo recettore, e mediare la trasduzione del segnale che porta all'attivazione di NF-κB. Si tratta di un regolatore che promuove l'apoptosi, ed è in grado di limitare il potenziale proliferativo delle cellule CD8 T e quindi proteggere il corpo contro l'autoimmunità. Due varianti di trascrizione tramite splicing alternativo di questo gene che codificano due isoforme della proteina.[1]
CD30 è associato al linfoma anaplastico a grandi cellule. Viene espresso nel carcinoma embrionale, ma non nel seminoma ed è quindi un indicatore utile per distinguere tra questi tumori delle cellule germinali.[2] CD30 e CD15 sono espressi in caso di linfoma di Hodgkin.[3]
Interazioni[modifica | modifica wikitesto]
CD30 effettua interazioni proteina-proteina con: TRAF5,[4] TRAF1,[5] TRAF2.[4][5] and TRAF3.[5]
Note[modifica | modifica wikitesto]
- ^ Entrez Gene: TNFRSF8 tumor necrosis factor receptor superfamily, member 8, su ncbi.nlm.nih.gov.
- ^ (ZH) Teng LH, Lu DH, Xu QZ, Fu YJ, Yang H, He ZL, [Expression and diagnostic significance of OCT4, CD117 and CD30 in germ cell tumors], in Zhonghua Bing Li Xue Za Zhi, vol. 34, n. 11, 2005, pp. 711–5, PMID 16536313.
- ^ Gorczyca W, Tsang P, Liu Z, et al., CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis, in Int. J. Oncol., vol. 22, n. 2, febbraio 2003, pp. 319–24, PMID 12527929.
- ^ a b S Aizawa, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J, Watanabe T, Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation, in J. Biol. Chem., vol. 272, n. 4, Jan. 1997, pp. 2042–5, DOI:10.1074/jbc.272.4.2042, PMID 8999898.
- ^ a b c S Ansieau, Scheffrahn I, Mosialos G, Brand H, Duyster J, Kaye K, Harada J, Dougall B, Hübinger G, Kieff E, Herrmann F, Leutz A, Gruss H J, Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation, in Proc. Natl. Acad. Sci. U.S.A., vol. 93, n. 24, novembre 1996, pp. 14053–8, DOI:10.1073/pnas.93.24.14053, PMC 19493, PMID 8943059.
Bibliografia[modifica | modifica wikitesto]
- Schneider C, Hübinger G, Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family., in Leuk. Lymphoma, vol. 43, n. 7, 2003, pp. 1355–66, DOI:10.1080/10428190290033288, PMID 12389614.
- Horie R, Higashihara M, Watanabe T, Hodgkin's lymphoma and CD30 signal transduction., in Int. J. Hematol., vol. 77, n. 1, 2003, pp. 37–47, DOI:10.1007/BF02982601, PMID 12568298.
- Tarkowski M, Expression and a role of CD30 in regulation of T-cell activity., in Curr. Opin. Hematol., vol. 10, n. 4, 2004, pp. 267–71, DOI:10.1097/00062752-200307000-00003, PMID 12799531.
- Granados S, Hwang ST, Roles for CD30 in the biology and treatment of CD30 lymphoproliferative diseases., in J. Invest. Dermatol., vol. 122, n. 6, 2004, pp. 1345–7, DOI:10.1111/j.0022-202X.2004.22616.x, PMID 15175022.
- Dürkop H, Latza U, Hummel M, et al., Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease., in Cell, vol. 68, n. 3, 1992, pp. 421–7, DOI:10.1016/0092-8674(92)90180-K, PMID 1310894.
- Fonatsch C, Latza U, Dürkop H, et al., Assignment of the human CD30 (Ki-1) gene to 1p36., in Genomics, vol. 14, n. 3, 1992, pp. 825–6, DOI:10.1016/S0888-7543(05)80203-4, PMID 1330892.
- Josimovic-Alasevic O, Dürkop H, Schwarting R, et al., Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay., in Eur. J. Immunol., vol. 19, n. 1, 1989, pp. 157–62, DOI:10.1002/eji.1830190125, PMID 2537734.
- Stein H, Gerdes J, Schwab U, et al., Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population., in Int. J. Cancer, vol. 30, n. 4, 1983, pp. 445–59, DOI:10.1002/ijc.2910300411, PMID 6754630.
- Jung W, Krueger S, Renner C, et al., Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources., in Mol. Immunol., vol. 31, n. 17, 1995, pp. 1329–34, DOI:10.1016/0161-5890(94)90051-5, PMID 7527901.
- Shiota M, Fujimoto J, Semba T, et al., Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3., in Oncogene, vol. 9, n. 6, 1994, pp. 1567–74, PMID 8183550.
- Lee SY, Park CG, Choi Y, T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors., in J. Exp. Med., vol. 183, n. 2, 1996, pp. 669–74, DOI:10.1084/jem.183.2.669, PMC 2192463, PMID 8627180.
- Gedrich RW, Gilfillan MC, Duckett CS, et al., CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins., in J. Biol. Chem., vol. 271, n. 22, 1996, pp. 12852–8, DOI:10.1074/jbc.271.22.12852, PMID 8662842.
- Horie R, Ito K, Tatewaki M, et al., A variant CD30 protein lacking extracellular and transmembrane domains is induced in HL-60 by tetradecanoylphorbol acetate and is expressed in alveolar macrophages., in Blood, vol. 88, n. 7, 1996, pp. 2422–32, PMID 8839832.
- Ansieau S, Scheffrahn I, Mosialos G, et al., Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation., in Proc. Natl. Acad. Sci. U.S.A., vol. 93, n. 24, 1997, pp. 14053–8, DOI:10.1073/pnas.93.24.14053, PMC 19493, PMID 8943059.
- Aizawa S, Nakano H, Ishida T, et al., Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation., in J. Biol. Chem., vol. 272, n. 4, 1997, pp. 2042–5, DOI:10.1074/jbc.272.4.2042, PMID 8999898.
- Lee SY, Lee SY, Choi Y, TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation., in J. Exp. Med., vol. 185, n. 7, 1997, pp. 1275–85, DOI:10.1084/jem.185.7.1275, PMC 2196258, PMID 9104814.
- Boucher LM, Marengère LE, Lu Y, et al., Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily., in Biochem. Biophys. Res. Commun., vol. 233, n. 3, 1997, pp. 592–600, DOI:10.1006/bbrc.1997.6509, PMID 9168896.
- Duckett CS, Thompson CB, CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival., in Genes Dev., vol. 11, n. 21, 1997, pp. 2810–21, DOI:10.1101/gad.11.21.2810, PMC 316646, PMID 9353251.
- Mizushima S, Fujita M, Ishida T, et al., Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5)., in Gene, vol. 207, n. 2, 1998, pp. 135–40, DOI:10.1016/S0378-1119(97)00616-1, PMID 9511754.
- Kurts C, Carbone FR, Krummel MF, et al., Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells., in Nature, vol. 398, n. 6725, 1999, pp. 341–4, DOI:10.1038/18692, PMID 10192335.
Collegamenti esterni[modifica | modifica wikitesto]
- (EN) CD30 Antigens, in Medical Subject Headings (MeSH), National Library of Medicine, 2009.
